Advanced Gastric Adenocarcinoma Clinical Trials

5 recruiting

Advanced Gastric Adenocarcinoma Trials at a Glance

10 actively recruiting trials for advanced gastric adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Anaconda, Ankeny, and ‘Aiea. Lead sponsors running advanced gastric adenocarcinoma studies include Beijing Biotech, Leiden University Medical Center, and Alliance for Clinical Trials in Oncology.

Browse advanced gastric adenocarcinoma trials by phase

Treatments under study

About Advanced Gastric Adenocarcinoma Clinical Trials

Looking for clinical trials for Advanced Gastric Adenocarcinoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Gastric Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Gastric Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled370 locationsNCT06203600
Recruiting
Phase 2

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Metastatic Gastric AdenocarcinomaAdvanced Esophageal AdenocarcinomaAdvanced Gastric Adenocarcinoma+1 more
UNICANCER88 enrolled4 locationsNCT06846346
Recruiting
Phase 1Phase 2

Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer

Advanced Gastroesophageal Junction AdenocarcinomaAdvanced Gastric Adenocarcinoma
Beijing Biotech36 enrolled1 locationNCT07551362
Recruiting
Phase 3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology382 enrolled791 locationsNCT05677490
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Early Phase 1

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+30 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT05041153
Recruiting
Phase 2Phase 3

[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

Locally Advanced Gastric Adenocarcinoma
Leiden University Medical Center250 enrolled10 locationsNCT07018661
Recruiting
Phase 2

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust50 enrolled9 locationsNCT06250036
Recruiting
Phase 3

Study of Comparing of With and Without Sequential Therapy of S-1

Locally Advanced Gastric AdenocarcinomaChemotherapy Effect
Zhejiang University70 enrolled1 locationNCT05813015
Recruiting
Phase 2

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital124 enrolled1 locationNCT04908566